Simplify access with Enterprise SSO for WordPress portals. Secure, seamless single sign-on integration for your enterprise users.
A PubMed search through June 30, 2025 identified 10 eligible comparative studies, pooling 5203 patients and using random-effects modeling to estimate mortality and cardiovascular hospitalization risk ...
Vutrisiran reduced mortality and cardiovascular events in ATTR-CM patients across all age groups, including those aged 80 and older. The HELIOS-B trial demonstrated consistent benefits in reducing all ...
The same abnormal proteins that can build up in your heart when you have transthyretin cardiac amyloidosis (ATTR-CM) can also leave deposits in your spine, resulting in spinal stenosis. Spinal ...
The low positive predictive value indicates that a positive diagnosis using planar imaging would result in an incorrect diagnosis of ATTR-CM 42% of the time. Calculating visual scores using ...
Alexandria Nyembwe is a registered nurse and health writer. She has worked in street medicine serving populations experiencing homelessness in Skid Row Los Angeles as well as in cardiovascular care in ...
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that makes the heart stiff and less flexible, making it harder for the heart to pump. ATTR-CM doesn't always cause symptoms. When it does, ...
Fatigue is one of the most frustrating symptoms of transthyretin cardiac amyloidosis (ATTR-CM). It can reduce your overall quality of life, limiting your ability to complete daily tasks and ...
The last time I spoke about Intellia Therapeutics (NTLA), it was with a Seeking Alpha article entitled "Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication" With respect to this ...
Alnylam’s closely watched launch of its rare disease drug Amvuttra continued to outpace Wall Street expectations. Riding its March expansion into the heart condition of transthyretin amyloid ...
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best performing large cap stocks to buy. On September 29, Alnylam Pharmaceuticals announced new data analyses from the HELIOS-B Phase 3 study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results